LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1,900,846 | $5,116,979 | $5,241,260 | $3,374,961 |
| - Cash | $28,084 | $49,466 | $246,351 | $222,659 |
| + Debt | $414,401 | $368,586 | $424,465 | $554,644 |
| Enterprise Value | $2,287,163 | $5,436,099 | $5,419,374 | $3,706,945 |
| Revenue | – | – | $135,527 | $168,706 |
| % Growth | – | – | -19.7% | – |
| Gross Profit | – | – | $34,408 | $133,807 |
| % Margin | – | – | 25.4% | 79.3% |
| EBITDA | – | – | -$82,617 | -$72,354 |
| % Margin | – | – | -61% | -42.9% |
| Net Income | – | – | -$181,410 | -$77,770 |
| % Margin | – | – | -133.9% | -46.1% |
| EPS Diluted | – | – | -1.81 | -0.85 |
| % Growth | – | – | -112.9% | – |
| Operating Cash Flow | – | – | $0 | $0 |
| Capital Expenditures | – | – | $0 | $0 |
| Free Cash Flow | – | – | $0 | $0 |